Congenital diaphragmatic hernia (CDH) carries a high mortality risk secondary to pulmonary hypoplasia and respiratory failure. In experimental animals, fetal tracheal occlusion (TO) induces lung growth and morphologic maturation. We measured indicators of pulmonary function in 20 infants who were enrolled in a randomized trial of fetal TO as treatment for severe CDH [nine with conventional treatment (controls); 11 with TO]. We hypothesized that TO would improve lung function. At birth, the TO group had a lower mean gestational age (30.8 Ϯ 2.0 versus 37.4 Ϯ 1.0 wk; p ϭ 0.0002). All infants required assisted ventilation. Mortality did not differ between groups (64 versus 78%, TO and control, respectively; p ϭ 0.64). We measured respiratory mechanics at four study points: 1) first 24 h, 2) before CDH operative repair (5.9 Ϯ 2.2 d), 3) immediately after repair (7.0 Ϯ 2.2d), and 4) before elective extubation (32.5 Ϯ 16.1 d). We calculated perioperative oxygenation index and alveolar-arterial oxygen difference to assess efficiency of pulmonary gas exchange. Data were analyzed by univariate and repeated measures techniques. Respiratory system compliance (Crs) was low. The rate of increase in Crs over the four study points was greater in the TO group than in control subjects. Crs in the TO group was significantly greater at study 2 (0.28 Ϯ 0.12 versus 0.17 Ϯ 0.04
Congenital diaphragmatic hernia (CDH) occurs 1 in 3000 live births (1) . A defect in formation of the hemidiaphragm results in fetal and neonatal pulmonary parenchymal and vascular hypoplasia (2) (3) (4) (5) (6) (7) . This is further complicated by a reactive pulmonary vascular bed that is poorly responsive to vasodilator therapy (8 -11) . As a result, newborns with CDH may require prolonged intensive support with oxygen, assisted ventilation, and extracorporeal membrane oxygenation (ECMO) to maintain adequate ventilation and oxygenation (6, (12) (13) (14) . Individual centers have reported recent improvements in survival rates to Ͼ75% for all newborns who are admitted with CDH (15) (16) (17) . However, other studies that included multiple centers have reported that mortality from CDH has remained high (45%) for liveborn infants (18) and those who are admitted to a surgical center (1, 19) , despite advances in neonatal and surgical care. Population-based studies have shown that infants whose CDH is diagnosed antenatally are at highest risk for neonatal death (50 -65%) (1, 18) .
Previous studies of infants with CDH have shown that compliance is low and may decrease acutely after surgical repair of the hernia (20, 21) . With delayed hernia repair, compliance increases from birth to time of repair (22) . Some investigators have found that higher preoperative compliance is associated with improved outcome, including survival (21) (22) (23) (24) . With CDH, efficiency of gas exchange is poor with respect to both ventilation and oxygenation, and the severity of impairment of gas exchange in the newborn period has also been associated with differences in survival (5, 14, 23) . Right-to-left shunting away from a high-resistance pulmonary vascular bed through the foramen ovale or a patent ductus arteriosus results in hypoxemia. This shunt progressively decreases in infants who survive (25, 26) .
Because of the high mortality associated with CDH, temporary fetal tracheal occlusion (TO) was developed for high-risk fetuses to attempt to enhance fetal lung growth and improve postnatal lung function. Experimental animal models of CDH and fetal TO in rodents, rabbits, and sheep have demonstrated increased fetal lung growth and morphologic maturation, and normalization of the pulmonary vasculature (27) (28) (29) (30) (31) (32) , although there is evidence of a deleterious effect of TO on alveolar type II cell number and function (33) (34) (35) . In fetal sheep with CDH, variable effects on gas exchange have been seen after fetal TO over several hours of postnatal stabilization, with some investigators demonstrating improvements (28, 36) and others finding no differences (37) . We undertook a randomized, controlled trial of endoscopic TO in fetuses with severe, isolated left CDH to compare survival at 90 d with fetal intervention with that with standard care (38) . Twenty-four fetuses were enrolled in the trial; 20 were born at our center (nine control subjects with standard care, 11 with TO). To evaluate lung function in these 20 infants who were receiving mechanical ventilation, we performed pulmonary function tests with an in-line pneumotachometer at four critical time points: 1) in the first 24 h after birth, 2) within 24 h before CDH operative repair, 3) within 24 h after CDH repair, and 4) before elective tracheal extubation. In addition, we evaluated efficiency of gas exchange during the perioperative period. We hypothesized that TO for severe left CDH would improve lung function in the newborn period. Secondarily, we hypothesized that lung function would be better in patients who ultimately survived and would be worse in patients in the most severe group (defined by prenatal measures).
METHODS
This study was approved by the University of California San Francisco (UCSF) Committee on Human Research. Written, informed consent was obtained before enrollment of fetal subjects. All studies took place in the UCSF Intensive Care Nursery. Subjects were born from July 1999 through August 2001.
Randomized trial: inclusion/exclusion criteria, fetal intervention, and antenatal care. The detailed trial protocol and outcome have been described previously (38) . Briefly, fetuses were evaluated at UCSF at 22-27 wk gestational age (GA). Fetal inclusion criteria for the trial included ultrasound diagnosis of a severe, isolated left CDH [defined as liver herniated into the thorax, lung-to-head ratio (LHR) Ͻ1.4, no associated anomalies, normal fetal karyotype, and normal fetal echocardiogram]. LHR has previously been shown to be a powerful predictor of mortality in this population (39) . Fetal endoscopic TO was accomplished at 24 -27 wk GA with either an external tracheal clip (40) (two patients) or a detachable silicone balloon (Boston Scientific/Target Therapeutics, Natick, MA) that was inflated with isosmotic contrast material (41) (nine patients).
All mothers who underwent fetal intervention were treated perioperatively with a standardized protocol of tocolysis. A single maternal glucocorticoid dose [betamethasone (BMZ) 12 mg i.m.] was given before TO to attempt to enhance the effect of the intervention on fetal lung growth (42) . A course of maternal BMZ to accelerate fetal lung maturation was administered when preterm delivery (Յ34 wk) was thought to be imminent. Delivery of fetuses after TO was determined by concerns for fetal or maternal well-being. This resulted in preterm delivery of all newborns in the TO group (Table 1) . Newborns who underwent TO were delivered by cesarean section (ex utero intrapartum therapy procedure (43)), which allowed evaluation of the fetal airway, release of TO, endotracheal intubation, administration of prophylactic exogenous surfactant (Exosurf Neonatal 3 mL/kg; Glaxo Wellcome, Research Triangle, NC), and initiation of pulmonary ventilation while the fetus was maintained on umbilical placental circulation.
Control infants were delivered vaginally after labor at Ն36 wk GA. An antepartum course of maternal BMZ was administered when the amniotic fluid lung profile was immature ( Table 1 ). The trachea was intubated immediately after birth, and prophylactic surfactant was administered in most of the infants to attempt to standardize care between the two groups ( Table 1) .
Study population. Lung function data were collected on the 20 newborns who were delivered at UCSF (nine control subject, 11 TO). As noted, all newborns in the TO group were preterm (Յ36 wk GA), with significantly lower GA and birth weight than control subjects (Table 1) . Mean LHR of control subjects and those who underwent TO were not significantly different ( Table 1 ). All infants had severe diaphragmatic defects that required prosthetic patch repair. There were no differences in age at CDH repair or age at elective tracheal extubation. Survival was 70% (14 of 20), with no difference between groups (Table 1) . Of the infants who had measurements of pulmonary mechanics, seven of 20 (35%) had an LHR Յ0.90 [most severe CDH (38) ].
Neonatal respiratory care. Conventional mechanical ventilation was the ventilatory mode of choice, with ventilator rates up to 90 breaths per minute, short inspiratory times, and low positive end expiratory pressure (PEEP; 2-3 cm H 2 O). Inspiratory pressure was set to achieve stable, acceptable oxygenation.
LUNG FUNCTION AFTER TRACHEAL OCCLUSION
All neonates were initially ventilated with 100% O 2 , which was weaned as tolerated. Mechanical ventilation was managed to maintain an arterial carbon dioxide pressure (PaCO 2 ) in the range of 45-60 mm Hg (permissive hypercapnia) and righthand (preductal) oxygen saturations Ն90%. Higher PaCO 2 values and lower oxygen saturations were tolerated in the first hours of life. Right radial arterial catheters (pre-ductus arteriosus) were used for monitoring arterial oxygen pressure (PaO 2 ) values, if possible, particularly in the event of a large right-toleft shunt at the level of the ductus arteriosus. PaO 2 alone was not used as a criterion for ventilator changes. Inhaled nitric oxide (iNO; INOmax; INO Therapeutics, Clinton, NJ) was administered for severe, prolonged arterial desaturation or failure to wean fraction of inspired oxygen (FIO 2 ) over first several days of life. The starting dose of iNO was 20 ppm. A trial of high-frequency ventilation (HFV) was performed when we were unable to provide adequate ventilation or oxygenation at maximal conventional ventilator settings. HFV was used preferentially in cases of an air leak (pneumothorax in two TO cases). ECMO was also used as rescue therapy (one control subject). Newborns received additional surfactant doses when their clinical course and chest radiograph were consistent with hyaline membrane disease.
The diaphragmatic hernia was repaired when the respiratory status had stabilized with weaning of ventilator settings and FIO 2 (age 6.4 Ϯ 2.2 d; Table 1 ). Infants remained pharmacologically paralyzed and sedated from birth until 24 h after CDH repair. After CDH repair, ventilator settings were weaned as tolerated, with liberal use of the pressure supported-assist control mode, and elective extubation of the trachea was attempted when low ventilator support was achieved. Once weaned from ventilatory support, infants remained on supplemental oxygen until able to maintain oxygen saturations (SPO 2 ) Ͼ95% on room air. Infants who were unable to maintain SPO 2 Ͼ95% on room air were discharged on supplemental oxygen ( Table 1) .
Measurement of lung mechanics. Pulmonary function tests studies were performed at four time points: 1) in the first 24 h after birth, 2) within 24 h before CDH operative repair, 3) within 24 h after CDH repair, and 4) before elective tracheal extubation. Patients remained pharmacologically paralyzed for their clinical management through the first three measurements. The mean age at each study point did not differ between the control and TO groups (data not shown).
All studies were performed on mechanically ventilated infants using an in-line pneumotachometer connected to a neonatal respiratory function monitor (CO 2 SMO Plus; Novametrix Medical Systems, Wallingford, CT). Ventilator PEEP was constant at all study points; it was adjusted on all subsequent studies to equal that of the initial study (2-3 cm H 2 O). Infants who were on HFV were given manually assisted ventilation with bag and endotracheal tube for the purpose of the study at a PEEP of 2-3 cm H 2 O (and equal to that of previous studies). The breath-to-breath measurements were downloaded directly to the CO 2 SMO Plus system software. Measurements were subsequently exported to a spreadsheet (Excel; Microsoft, Redmond, WA), where 8 -20 uniform, representative breaths (selected from tracings) were used for analysis. A summary measurement was obtained for the variables of interest from each study [respiratory system compliance (Crs), minute ventilation (V E ), and peak expiratory flow (PEF)] by calculating a mean value and then dividing by the patient's weight to normalize the measurements for body size (44) .
Pulmonary gas exchange. Arterial pH and blood gas tensions (PaCO 2 , PaO 2 ) measured for purposes of clinical management from birth through the perioperative period were gathered for analysis ( Data are mean Ϯ SD (range). * All subjects survived to CDH repair. Deaths before extubation included one control subject from pulmonary hypertension (30 d), one TO subject from respiratory insufficiency (10 d), and one TO subject from sepsis (14 d).
† Two additional subjects died before discharge: one control subject from pulmonary hypertension and chronic lung disease (236 d) and one TO subject from pulmonary hypertension (71 d). One additional TO subject who was discharged on supplemental O 2 died from pulmonary hypertension after readmission (203 d). 820 on postoperative day 3). Blood source, ventilator settings, and pre-and post-ductus arteriosus SPO 2 differences were also collected. The single patient who required ECMO support was cannulated on the first day of life and decannulated preoperatively after 8 d of support. Arterial blood gas samples obtained while on ECMO were excluded as they did not reflect this patient's pulmonary gas exchange. Blood source was classified as "preductal" when it was obtained from the right upper extremity and "postductal" when it was obtained from the abdominal aorta or a lower extremity. Blood samples from the left radial artery (11% of total samples) were classified as preductal unless information from paired blood gas samples or simultaneous pre-and post-ductus arteriosus SPO 2 values were consistent with a postductal position (one of five patients). The majority of these samples were obtained in the postoperative period.
The following were calculated from the collected data:
Oxygenation Index (OI) ϭ Paw ϫ FiO 2 ϫ 100/PaO 2 ͑10͒
Where P aw is mean airway pressure, P B ϭ 760 mm Hg, 47 mm Hg is P H2O at 37°C, and RQ ϭ 1. iNO response. The PaO 2 just before beginning iNO and the subsequent values obtained at least 20 min after beginning therapy were recorded. Pre-and postductal SPO 2 were collected before and on iNO therapy. Because this was not a controlled study of iNO response, we chose stringent criteria to define an acute iNO responder: an increase in postductal SPO 2 of Ͼ5% and an increase in PaO 2 of Ն50 mm Hg in arterial blood sampled from the same source. Previously, investigators have used an increase in PaO 2 of Ͼ20 mm Hg as a definition of response to iNO in the CDH population (10) .
Data analysis. Statistical analyses were performed with Stata 6.0 (Stata Corp., College Station, TX). Variables that were not normally distributed were analyzed with tests for nonparametric data. Statistical tests included t test, MannWhitney rank sum test, 2 or Fisher exact test, and linear regression. Repeated measures models were constructed using generalized estimating equations. Huber-White sandwich estimators of variance were used to allow robust standard errors estimations in the event of improper specification of the correlation structure between repeated measurements (45) . The effect of study point was explored as a linear and quadratic function for all measures of lung mechanics. The natural log of gas exchange measures and P aw changed linearly with time (age in hours); therefore, it was used as the outcome variable for construction of linear models. Results are presented as mean Ϯ SD or percentage. P values presented in regression models are for individual predictor variable coefficients. All statistical tests were two-tailed, and results were considered significant at p Ͻ 0.05.
RESULTS

Lung mechanics. Crs (mL · cm H 2 O
Ϫ1 · kg Ϫ1 ) was low in both groups. It was higher in the TO group at study 2 and study 4 ( Table 2 ). There were no significant differences at any study point in comparing survivors and nonsurvivors or in classification of severity by LHR (Յ0.90 versus Ͼ0.90; data not shown). Repeated measures models of Crs revealed that both treatment group and study point were significant predictors of Crs. Crs was higher in newborns who had undergone TO, it increased over time, and it increased at a faster rate in the TO group because of a significant interaction between treatment group and study point (p ϭ 0.007; Fig. 1A ). To evaluate bias as a result of death of three patients before study 4, we analyzed the model with exclusion of these three patients. The model remained significant with minor changes in the magnitude of the effects of our predictor variables.
There were no significant differences in V E (mL · min Ϫ1 · kg
Ϫ1
) at any study point by treatment group (Table 2) , although V E tended to be higher in TO infants. There were also no differences between infants who survived and those who died (data not shown). Analysis of V E in relation to LHR revealed higher V E in the low LHR group only at study 2 (257 Ϯ 87 versus 171 Ϯ 65 mL · min Ϫ1 · kg Ϫ1 ; p ϭ 0.03). After accounting for differences in the patients' PaCO 2 during the study, this relationship was no longer significant (p ϭ 0.08).
A trend toward a higher V E in the TO group was revealed by repeated measures analysis (␤ ϭ 29, p ϭ 0.05). The study point was a significant predictor of V E . In this model, V E initially decreased (from study 1 to study 2) and then increased in the postoperative period (Fig. 1B) . There was no interaction between treatment group and study point. After accounting for differences in the patients' PaCO 2 during the study, the study point remained a significant predictor and the treatment effect was diminished (␤ ϭ 21, p ϭ 0.17); a lower PaCO 2 was associated with higher V E .
PEF was significantly higher in the TO group than in control subjects at all study points (Table 2 ). There were no differences in PEF between survivors and nonsurvivors or between LHR groups (data not shown). In repeated measures models, study point was not a significant predictor of PEF, but treatment group remained significant (␤ ϭ 0.65, p Ͻ 0.001). Pulmonary gas exchange. Representative values of OI and AaDO 2 at important clinical time points suggested that, as expected, OI and AaDO 2 decreased over time (Table 3) . Univariate linear regression confirmed that the patient's age at the time of the sample had a significant correlation with these outcomes [decreasing OI (p Ͻ 0.001) and AaDO 2 (p Ͻ 0.001) with increasing age in hours]. Other significant associations with a lower OI were increased LHR (p Ͻ 0.001) and higher pH (p Ͻ 0.001). iNO therapy was associated with a higher OI (p Ͻ 0.001). For AaDO 2 , increased LHR (p Ͻ 0.001) and a lower P aw (p Ͻ 0.001) were associated with a lower AaDO 2 . iNO therapy was associated with a higher AaDO 2 (p Ͻ 0.001).
In repeated measures models analysis of OI, treatment group was not a significant predictor variable (p ϭ 0.48). OI significantly decreased with increasing age at the time of the sample ( Fig. 2A) . In contrast, TO was significantly associated with a lower AaDO 2 (p ϭ 0.006). In addition, AaDO 2 decreased with advancing postnatal age (Fig. 2B) . There was no significant interaction between treatment group and age. When LHR, blood sample site, and iNO therapy were added to the model, TO was associated with a lower AaDO 2 (p ϭ 0.009) and treatment group still had no significant effect on OI (p ϭ 0.18). LHR was an independent predictor of both OI (p ϭ 0.002) and AaDO 2 (p Ͻ 0.001), with a decrease in these values with a higher LHR. A preductal blood gas source was significantly associated with a lower OI (p ϭ 0.009) but not AaDO 2 (p ϭ 0.78). iNO was not significantly associated with OI or AaDO 2 in these models.
In repeated measures models of other markers of gas exchange, P aw significantly decreased with advancing postnatal age (p ϭ 0.01), and there was a trend toward lower P aw in the TO group (p ϭ 0.09). PaCO 2 was tightly controlled over the study period; there was no significant association of PaCO 2 with postnatal age (p ϭ 0.87) or treatment group (p ϭ 0.56).
Seven (35%) of the patients had severe impairment of oxygenation (defined as OI Ͼ30) (10). This impairment persisted for Ͼ4 h in six of seven patients (three control subjects, three TO; p ϭ 1.0). iNO therapy. Nine patients (45%) were begun on iNO in the perioperative period (all before CDH repair; Table 1 ). The changes in PaO 2 , OI, and postductal SpO 2 are shown in Figure  3 . Three (33%) of the infants responded to iNO; all were control subjects. Although we chose more stringent criteria for an iNO response than previous investigators, in fact all patients whose PaO 2 increased Ͼ20 mm Hg also met our criteria by increasing their PaO 2 Ն50 mm Hg and their postductal SpO 2 Ͼ5%. The single patient who required ECMO support was a nonresponder.
DISCUSSION
We have demonstrated a modest improvement in newborn lung function after fetal TO for severe left CDH. These improvements consisted of increased Crs, increased PEF, and increased oxygenation, as measured by AaDO 2 . This is the first report of these physiologic measurements after fetal TO in humans. It is also the first study that compares these measurements in infants who had fetal TO with infants who had a Ϫ1 · kg Ϫ1 ) over the study period for each treatment group. There is a more rapid improvement in Crs over the study period in the TO group with a significant interaction between treatment group and study point. Regression equation: y ϭ 0.06 Ϫ 0.11(treatment) ϩ 0.09(study point) ϩ 0.12(treatment ϫ study point). (B) V E (mL · min Ϫ1 · kg Ϫ1 ) over the study period for each treatment group. Regression equation: y ϭ 335 ϩ 29(treatment) Ϫ 136(study point) ϩ 31(study point) 2 . □, Tracheal occlusion; Ⅵ, control. These elegant animal experiments have clearly documented intrauterine lung growth and morphologic maturation, with increased area for gas exchange (28, 30, 32, 35, 46) and variable effects on gas exchange with short-term assisted ventilation postnatally (28, 36) . In our study, the compliance measures were extremely low (47) , which other investigators have previously documented in CDH (21, 23, 24, 48) . Therefore, even a small impact on lung compliance could be clinically significant in this population. We did not perform lung volume measurements by gas dilution or lung morphologic examinations. However, the modest increases in Crs in this study could be secondary to increased fetal lung growth in the TO group (44) . Although V E had a wide range, the values were in the normal range (47) and were highly associated with PaCO 2 (higher V E associated with lower PaCO 2 ), which was tightly controlled throughout the perioperative period.
Nakayama et al. (49) used the deflation flow volume curve technique and passive expiratory flow volume curves to assess airway obstruction and resistance in paralyzed, intubated newborns with CDH in the first month of life after repair and stabilization. They found that this population did have significant airway obstruction that was partially reversible through bronchodilator therapy. An increased propensity to bronchial constriction was recently demonstrated in the nitrofen-induced CDH model in rats, which was associated with increased cyclooxygenase in the airway smooth muscle cells (50) . Therefore, the higher PEF measures after TO may demonstrate some effect of fetal intervention on airway remodeling. We corrected these measurements to the patients' weight to standardize the measurements for size. However, previous investigators have demonstrated that airway conductance does not have a linear relationship to size in healthy newborns, with the airways relatively more developed in small infants (44) . Therefore, the greater PEF that we observed in the TO group may be secondary to prematurity rather than an effect of TO itself. Conversely, the endotracheal tube internal diameter may contribute significantly to these measurements. This effect would favor lower flow in the smaller TO group with narrower, higher resistance tubes (51) .
Oxygenation is affected by parenchymal lung disease (atelectasis, edema, pneumothorax), alveolar surface area, and the pulmonary vasculature. The resistance of the pulmonary vasculature determines pulmonary blood flow, and in CDH, the resistance is determined by the size of the pulmonary vascular bed as well as its degree of vasodilation (25) . Thickening of the muscular layer of the pulmonary arteries occurs as early as 21 wk GA in fetuses with CDH and pulmonary hypoplasia (2) . TO in experimental animals with CDH accelerates lung growth (30, 35) and tends to normalize the pulmonary vascular morphology (27, 29, 52) and function (31, 36) . In the current study, TO fetuses had better oxygenation (as measured by AaDO 2 ). This may have been due to increased lung size, more normal pulmonary vasculature, or contributions of both effects.
Other factors may explain differences in oxygenation. Surfactant administration differed between groups, with a higher proportion of the TO group receiving prophylactic surfactant ( Table 1) . Surfactant administration in the ovine CDH model improves gas exchange; this has been attributed to improve- (53) and pulmonary vascular resistance (54) . However, it is unlikely that surfactant therapy accounts for the differences seen between the two groups because we would expect to see more of an effect early in the course. Another factor is related to the developmental changes in smooth muscle in the pulmonary vasculature. In preterm infants without CDH, the pulmonary vascular smooth muscle is less developed than that of term infants. The changes in muscularization through advancing gestation in CDH are unknown in humans, but the ovide model supports progressive pulmonary hypoplasia with advancing gestation (55) . Thus, the effect of prematurity in CDH may result in increased oxygenation. Ventilator strategies will also affect oxygenation. The ventilator management was consistent between groups, but there was a tendency to use lower P aw in the smaller TO group (which may account for the failure to see a difference in oxygenation through evaluation of OI). Our studies do not allow us to determine the mechanism by which TO increased oxygenation.
The significant association that we saw of decreased oxygenation with lower LHR [which may be a proxy for intrauterine lung volume (56) ] is an important observation. This could be related to smaller lung volume with lower LHR or a more abnormal pulmonary vasculature with lower LHR, as more pronounced vascular abnormalities are seen in more severe lung hypoplasia (4) .
The ability to respond to iNO therapy (seen in three subjects from the control group) points to a reactive pulmonary vascular bed as a cause of hypoxemia in a subset of the subjects. Newborns with CDH have variable responses to vasodilator therapy (8, 10) . The proportion of NO responders in our study cohort was similar to what has previously been seen (16%) in the controlled setting in the CDH population (10) .
CDH is a heterogeneous condition with varying degrees of anatomic severity and lung hypoplasia (23, 38) . Although we may have been able to decrease this heterogeneity through our strict antenatal inclusion criteria, it is likely to have been compounded by other sources of variability between and within the treatment groups. All subjects in the TO group were preterm, and all subjects in the control group were term, with no overlap between the GAs of these groups. We attempted to account for some of this difference through adjustment of lung mechanics measurements for body weight. However, we could not take into account other differences between the subjects, and the strong association of prematurity and fetal intervention confounds our ability to evaluate effects of GA on lung function. The more compliant chest wall of the preterm newborn would result in a relative increase in compliance in the TO group. Because subjects were pharmacologically paralyzed through the postoperative measurements (study 3), this effect should be less pronounced. An additional confounder was the wide range of duration of TO (16 -64 d) . This was also significantly correlated with the degree of prematurity. There are likely differing biologic effects of TO in humans, dependent on its duration (lung growth and differentiation, surfactant production, vascular growth and remodeling), as there are in animal models (30,46,52) . These effects may differ longitudinally, as the intrauterine and postnatal development and maturation of the lung in CDH are likely related to the degree of prematurity and duration of TO.
In this study, we have not been able to draw conclusions regarding the mechanisms of effects of fetal TO from either an anatomic or a biochemical perspective. Despite the limitations of this study population, our findings describe possible benefits of fetal TO in this population, with small, measurable differences in lung function. However, in view of the absence of any significant effect on survival, these modest improvements in pulmonary function in infants after TO are of questionable clinical significance.
